when do you see results with semaglutide TrimRX How Do You Know When
Description
Key findings: 29% reduction in coronary heart disease death, myocardial infarction, or ischemic stroke (3-point MACE) 21% reduction in broader cardiovascular events including revascularization (4-point MACE) Median LDL-C reduced to 45 mg/dL versus 106 mg/dL with placebo Benefits were consistent regardless of concomitant GLP-1 receptor agonist or SGLT2 inhibitor use
These include Semaglutide, Tirzepatide, Liraglutide, and lipotropic injections.
Address obesity and all comorbidities.
This process is called cellular autophagy and is something that my guest today, James Clement, is very familiar with.
Book an appointment with us today!
